Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
NEW YORK, March 17, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Galena Biopharma, Inc. securities (NASDAQ:GALE) from August 11, 2014 through January 31, 2017, both dates inclusive (the “Class Period”) of the April 14, 2017 lead plaintiff deadline in the class action first filed by Rosen Law Firm. This first filed lawsuit seeks to recover damages for Galena investors under the federal securities laws.
To join the Galena class action, go to http://www.rosenlegal.com/cases-1054.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Galena’s sales of Abstral were based on unsustainable sales and marketing practices; (2) such sales and marketing practices could subject Galena to a criminal investigation; and (3) as a result, Defendants’ statements about Galena’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1054.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
